Prescribing Info
This site is for US Health Care Professionals only
Banner image

Helping Patients Since 2009

AFINITOR has delivered efficacy and safety data backed by more than a decade of clinical use.1 First approved by the FDA in 2009,1 the figures speak for themselves:

– Over 7501 published articles2

– Over 1257 clinical trials3

– Over 1.1 million packs distributed4

Novartis Patient Support™

Novartis Patient Support is a program designed to help your eligible patients start, stay, and save on AFINITOR. To learn more, call 1-800-282-7630.

Universal Co-pay Program
Novartis Universal Co-Pay Card

Novartis Oncology Universal Co-pay Program

Patients may be eligible for immediate co-pay savings on their next prescription of AFINITOR® (everolimus) Tablets and AFINITOR DISPERZ® (everolimus tablets for oral suspension).

 

  • Eligible patients with private insurance may pay $0 per month

  • Novartis will pay the remaining co-pay, up to $15,000 per calendar year, per product*

 

Encourage your patients to find out if they are eligible to enroll in the Novartis Oncology Universal Co-pay Program by visiting Copay.NovartisOncology.com or calling 1-877-577-7756.

*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full Terms and Conditions, visit Copay.NovartisOncology.com or call 1-877-577-7756.
References: 1. Afinitor. Prescribing information. Novartis Pharmaceuticals Corp. 2. PubMed. Available at: Afinitor - Search Results - PubMed (nih.gov). Accessed March 10, 2022. 3. ClinicalTrials.gov. Available at Search of: everolimus - Results on Map - ClinicalTrials.gov. Accessed March 10, 2022. 4. Data on file. Afinitor Packs Distributed 2009-2021.